CPHI & PMEC China 2023 to see surge from pent up international ingredients demand
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The partnership will capitalize on the combined capabilities of the two organizations
The appointment is effective from May 01, 2023 for five years
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated